Key statistics
As of last trade ACADIA Pharmaceuticals Inc (ACAD:NSQ) traded at 22.40, -21.01% below its 52-week high of 28.35, set on Dec 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.87 |
|---|---|
| High | 23.13 |
| Low | 22.37 |
| Bid | 22.38 |
| Offer | 22.41 |
| Previous close | 23.39 |
| Average volume | 2.35m |
|---|---|
| Shares outstanding | 170.49m |
| Free float | 169.50m |
| P/E (TTM) | 9.87 |
| Market cap | 3.84bn USD |
| EPS (TTM) | 2.28 USD |
Data delayed at least 15 minutes, as of Mar 05 2026 19:29 GMT.
More ▼
- Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
- Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
- Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
- Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
- Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
- Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
More ▼
